GoAI
Get started
Inogen, Inc. logo

Inogen, Inc.

INGN

NASDAQHealthcareMedical - Devices

Open in GoAI

Previous close

$5.61

+$0.01 · +0.18%

Aug 21, 4:00 PM ET

INGN company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

69

Undervalued

Momentum

35

Weakening

Sentiment

53

Mixed

Risk resilience

43

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
US
CEO
Kevin R. Smith
Listed since
Feb 14, 2014
Employees
753

Market position

Day range

Current $5.61

52-week range

Current $5.61

Open
$5.62
Previous close
$5.60
Volume
140.35K
0.47× average
Average volume
296.76K
Average daily volume
Market cap
151.89M USD
Beta
1.6
Market reference 1
50-day average
$6.3554
-11.73% below average
200-day average
$6.4788
-13.41% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
96.37M USD
P/E (TTM)
-6.23×
P/B (TTM)
0.87×
P/S (TTM)
0.43×
EV / EBITDA
-35.43×
Earnings yield
-12.46%
Free cash flow yield
-11.83%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
48.89%
Operating margin
-8.45%
Net margin
-6.94%
Return on equity
-11.83%
Return on assets
-7.62%
Return on invested capital
-12.34%

Financial health

Debt / equity
0.09×
Current ratio
3.12×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends58%24%-9%-43%Gross margin, FY2021: 49.30%Gross margin, FY2022: 40.70%Gross margin, FY2023: 40.14%Gross margin, FY2024: 46.09%Gross margin, FY2025: 47.58%Operating margin, FY2021: 2.58%Operating margin, FY2022: -22.60%Operating margin, FY2023: -34.65%Operating margin, FY2024: -12.66%Operating margin, FY2025: -8.66%Net margin, FY2021: -1.77%Net margin, FY2022: -22.21%Net margin, FY2023: -32.46%Net margin, FY2024: -10.69%Net margin, FY2025: -6.52%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 49.30%. Gross margin FY2022 40.70%. Gross margin FY2023 40.14%. Gross margin FY2024 46.09%. Gross margin FY2025 47.58%. Operating margin FY2021 2.58%. Operating margin FY2022 -22.60%. Operating margin FY2023 -34.65%. Operating margin FY2024 -12.66%. Operating margin FY2025 -8.66%. Net margin FY2021 -1.77%. Net margin FY2022 -22.21%. Net margin FY2023 -32.46%. Net margin FY2024 -10.69%. Net margin FY2025 -6.52%.

Income trends

Revenue

348.67M USD+3.86%

Operating income

−30.21M USD+28.95%

Net income

−22.75M USD+36.62%
Income trends across reported periods425.9M USD231.25M USD36.6M USD−158.05M USDRevenue, FY2021: 358M USDRevenue, FY2022: 377.24M USDRevenue, FY2023: 315.66M USDRevenue, FY2024: 335.71M USDRevenue, FY2025: 348.67M USDOperating income, FY2021: 9.24M USDOperating income, FY2022: −85.24M USDOperating income, FY2023: −109.39M USDOperating income, FY2024: −42.52M USDOperating income, FY2025: −30.21M USDNet income, FY2021: −6.33M USDNet income, FY2022: −83.77M USDNet income, FY2023: −102.45M USDNet income, FY2024: −35.89M USDNet income, FY2025: −22.75M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 358M USD. Revenue FY2022 377.24M USD. Revenue FY2023 315.66M USD. Revenue FY2024 335.71M USD. Revenue FY2025 348.67M USD. Operating income FY2021 9.24M USD. Operating income FY2022 −85.24M USD. Operating income FY2023 −109.39M USD. Operating income FY2024 −42.52M USD. Operating income FY2025 −30.21M USD. Net income FY2021 −6.33M USD. Net income FY2022 −83.77M USD. Net income FY2023 −102.45M USD. Net income FY2024 −35.89M USD. Net income FY2025 −22.75M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue348.67M USD335.71M USD315.66M USD377.24M USD358M USD
Cost of goods sold182.78M USD180.96M USD188.96M USD223.71M USD181.52M USD
Gross profit165.89M USD154.74M USD126.7M USD153.53M USD176.48M USD
Research and development19.4M USD21.61M USD20.84M USD21.94M USD16.58M USD
Selling, general, and administrative165.07M USD175.65M USD182.35M USD164.67M USD150.67M USD
Operating expenses196.1M USD197.26M USD236.09M USD238.78M USD167.24M USD
Interest income2.15M USD5.19M USD6.57M USD2.84M USD129K USD
Depreciation and amortization20.66M USD21M USD18.15M USD23.51M USD21.63M USD
Operating income−30.21M USD−42.52M USD−109.39M USD−85.24M USD9.24M USD
Net income−22.75M USD−35.89M USD−102.45M USD−83.77M USD−6.33M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
82%
9 beats, 2 misses, 0 met estimates
Average EPS surprise
+15.54%
11 comparable reports
Latest EPS result
-0.14
Estimate -0.15 · Beat by 8.69%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.09-0.26-0.43-0.6Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual -0.41, estimate -0.56, surprise +26.79%, Beat. Q2 2025, reported May 7, 2025: actual -0.25, estimate -0.52, surprise +51.92%, Beat. Q3 2025, reported Aug 7, 2025: actual -0.15, estimate -0.22, surprise +31.82%, Beat. Q4 2025, reported Nov 5, 2025: actual -0.2, estimate -0.22, surprise +9.09%, Beat. Q1 2026, reported Feb 24, 2026: actual -0.26, estimate -0.36, surprise +27.78%, Beat. Q2 2026, reported May 7, 2026: actual -0.3, estimate -0.24, surprise -25.00%, Miss. Q3 2026, reported Aug 6, 2026: actual -0.14, estimate -0.153, surprise +8.69%, Beat. Q4 2026, reported Nov 4, 2026: actual —, estimate -0.11, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates99.04M89.39M79.74M70.09MQ1 '25BeatQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 80.08M USD, estimate 73.9M USD, surprise +8.36%, Beat. Q2 2025, reported May 7, 2025: actual 82.28M USD, estimate 92.73M USD, surprise -11.27%, Miss. Q3 2025, reported Aug 7, 2025: actual 92.28M USD, estimate 93.27M USD, surprise -1.06%, Miss. Q4 2025, reported Nov 5, 2025: actual 92.39M USD, estimate 88.6M USD, surprise +4.28%, Beat. Q1 2026, reported Feb 24, 2026: actual 81.72M USD, estimate 85.05M USD, surprise -3.91%, Miss. Q2 2026, reported May 7, 2026: actual 85.11M USD, estimate 82.35M USD, surprise +3.35%, Beat. Q3 2026, reported Aug 6, 2026: actual 95.08M USD, estimate 95.23M USD, surprise -0.16%, Miss. Q4 2026, reported Nov 4, 2026: actual —, estimate 92.33M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

11 ratings
Strong buy00%
Buy655%
Hold436%
Sell19%
Strong sell00%

INGN peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding INGN

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
4.77M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
3.55M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.75M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
1.22M
Weight
0.01%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.81+0.45%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
887.66K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Federated Hermes MDT Small Cap Core ETF logoFederated Hermes MDT Small Cap Core ETFFSCC
Market value
534.18K
Weight
0.15%
AUM
309.3M USD
Expense ratio
0.50%
Price / 1D
$35.89+0.79%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
483.05K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$198.39+1.10%
U.S. Micro Cap Portfolio ETF logoU.S. Micro Cap Portfolio ETFDFMC
Market value
473.6K
Weight
0.01%
AUM
8.06B USD
Expense ratio
0.43%
Price / 1D
$60.95+0.73%

Continue in GoAI

Research INGN

research.disclaimer